Borghi 2018.

Methods	RCT; double‐blind, placebo‐controlled, cross‐over study; computer‐generated randomisation Follow‐up: 90 days. Outcome measurements at baseline, 5 minutes, 1, 6, 12, and 24 hours after each injection; and after 5, 15, 30, and 90 days
Participants	Population: 80 participants, May 2012 to April 2014 Inclusion criteria: people suffering from LBP of < 6 months duration, older than 18 years, written informed consent; non‐surgical lumbago including disc syndrome, spinal stenosis, postural back pain Exclusion criteria: paediatric patients, people with allergies to meloxicam (or other non‐steroidal drugs), people with contraindications to the local puncture (such as infection of the skin at the puncture level), and people unable to express an informed consent to the treatment or available for the follow‐up
Interventions	NSAID (i): periradicular meloxicam injections (N = 40) Reference treatment (ii): periradicular saline injections (N = 20) The amount of injections differed per participant depending on NRS score change (1 to 3 injections).
Outcomes	Pain reduction, need for analgesic medication, level of physical activity, quality of sleep
Notes	1. LBP < 6 months included; no subgroup analysis of only (sub)acute LBP 2. We contacted the corresponding author to ask for clarification (21 September 2019)